Immunotherapy has emerged as the most promising cancer treatments in the last decade with a major impact in oncology by inducing durable responses. However, relatively few patients are able to benefit from this advance. With a growing number of clinical trials testing immune checkpoint inhibitors (ICI) or CAR-T cells, one of the main objectives for researchers now is to extend immunotherapeutic approaches to more patients and tumor types while decreasing the risk of clinical trial failures.
In this promising race against cancer, biomarkers represent one of the cornerstones of drug development programs and can be used in clinical trials to select patients and, ultimately, be employed as companion diagnostics. Biomarkers are also used for research purposes to better understand the mechanism of action for drugs, enable internal decision-making, and the ability to build clinico-genomic datasets.
In this webinar, Dr Chiara Cremolini will present results obtained in the context of a clinical trial on the usefulness of Immunoscore IC® testing in metastatic colorectal cancer (mCRC) patients who received an Immune Checkpoint Inhibitor (ICI) treatment in combination with chemotherapy.
In the session, Dr, Jérôme Galon will also explain how the Veracyte Biopharma Atlas, a comprehensive and proprietary cancer reference database comprised of genomic and immunomic biomarkers that are assessed by Veracyte’s best-in-class assays, can help biopharma organizations in their biomarker strategy by strengthening their biologic hypothesis and de-risking clinical trials.
The Immunoscore IC is available for clinical research. It has not been cleared nor approved by the FDA and is not for use in diagnostic procedures.
‘Immunoscore IC® is a French registered trademark of Veracyte’
Chiara Cremolini, MD, PhD, Professor of Medical Oncology, University of Pisa
Chiara Cremolini is an Associate Professor of Medical Oncology at the University of Pisa in Italy.
Following an MD Degree in 2008, a Master of Science in Clinical Trials, and a Specialty in Medical Oncology at the University of Pisa, she gained her PhD in Clinical Pathophysiology. She is mainly committed to the clinical management of patients affected by gastrointestinal malignancies and is involved in clinical and translational research projects in the field of colorectal oncology. She is responsible for the scientific activities of the Clinical Trials’ Office at the Unit of Oncology at Santa Chiara Hospital in Pisa. She actively contributes to clinical trials by Gruppo Oncologico del Nord Ovest (GONO), an Italian Foundation involved in the design and conduction of clinical and translational studies in the field of several solid malignancies, serving as Scientific Secretary between 2015 and 2021, and as President since 2021. She is an ESMO faculty member for GI tumors.
She has been particularly involved in trials investigating intensified chemotherapy regimens as upfront treatment of metastatic colorectal cancer patients. She has authored more than 200 papers on colorectal cancer.
With regard to translational activities, she is mainly interested in the identification of molecular predictors of benefit from systemic treatments and to this end has secured collaborations with numerous international institutions.Message Presenter
Jérôme Galon, PhD, Director, Inserm, Cordeliers Research Center, Paris, France and of Veracyte
Jérôme Galon is the Director of Research at Inserm (French National Institute of Health and Medical Research) and Head of The Laboratory of Integrative Cancer Immunology, in Paris, France. He is also the Associate Director and Co-Founder of the European Academy of Tumor Immunology (EATI), board member of the Society for Immunotherapy of Cancer (SITC) and was the Chief Scientific Officer (CSO) Immuno-Oncology at HalioDx, which is now part of Veracyte. His work on the comprehensive analysis of the tumor microenvironment led to the concept of immune contexture in cancer.
Jérôme Galon pioneered Immunoscore and is the Principal Investigator of the Worldwide Immunoscore Consortium. He has been a consultant and/or served on the scientific advisory board of 28 biotech and pharmaceutical companies. His contributions have been recognized with numerous awards, including the William B Coley Award, USA (2010), the prestigious European Patent Office (EPO, EU) as European Inventor 2019 for Immunoscore®, and the Senior Research Prize Jean Valade from the Fondation de France (2020). On January 1st, 2020, he was appointed Knight of the Legion of Honour by Presidential decree.Message Presenter
Who Should Attend?
Biopharma teams involved in immuno-oncology with responsibilities including, but not limited to:
- Biomarker Discovery
- Translational Medicine
- Clinical Development
- CDx Development
What You Will Learn
Attendees will learn about:
- Promising new results obtained with the Immunoscore IC® PD-L1/ CD8 in a clinical trial for metastatic colorectal cancer using immune checkpoint therapy in combination with standard of care
- The new Veracyte Biopharma Atlas database, a comprehensive and proprietary cancer reference database made of genomic and immunomic biomarkers
Veracyte is a global diagnostics company that improves patient care by answering important clinical questions to inform diagnosis and treatment decisions. Our growing menu of advanced diagnostic tests help patients avoid risky, costly procedures and interventions, and reduce time to appropriate treatment. Our tests address eight of the 10 most prevalent cancers by incidence in the United States. In addition to making our tests available in the United States through our central laboratories, our exclusive license to a best-in-class diagnostics instrument positions us to deliver our tests to patients worldwide through laboratories that can perform them locally.
With our immuno-oncology offerings, Veracyte translates the complexities of the tumor immune response into a clear path forward. Our extensive biorepositories, immuno-oncology biomarker testing and analytical services help our biopharmaceutical partners to advance their therapeutic discovery, development and commercialization programs.